Evolocumab attenuates myocardial ischemia/reperfusion injury by blocking PCSK9/LIAS-mediated cuproptosis of cardiomyocytes
Basic Research in Cardiology · 11.02.2025 · 120 (2) · 301-320
DOI: 10.1007/s00395-025-01100-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic Research in Cardiology, online erschienen am 11.02.2025. Verfasst von Zi-Zhuo Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Myocardial Reperfusion Injury, Proprotein Convertase 9, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Natural Science Foundation of Liaoning Province, Department of Education of Liaoning Province.
Abstract (Originalsprache)
Myocardial ischemia‒reperfusion (I/R) injury is the crucial cause of poor prognosis after revascularization in patients with myocardial infarction (MI) due to the lack of specific therapeutic drugs. Proprotein convertase subtilisin/Kexin type 9 (PCSK9) is related to the pathogenesis and progression of various cardiovascular diseases. However, the specific role of PCSK9 in I/R-induced cardiac injury remains to be further investigated. In this study, wild-type (WT) C57BL/6J mice were administered evolocumab (a monoclonal antibody of PCSK9) before I/R surgery. Cardiac damage and function were assessed by echocardiography and TTC/Evans Blue staining. Inflammation, oxidative stress, mitochondrial dysfunction, and cuproptosis were evaluated by histopathology and qPCR. The interaction between proteins was confirmed by protein docking and co-immunoprecipitation. Our data revealed that PCSK9 level was increased in I/R-induced mouse serum and hearts and in serum of MI patients. Furthermore, evolocumab significantly improved cardiac injury and dysfunction, inflammation, oxidative stress, and cuproptosis. Mechanistically, evolocumab obstructs the direct interaction of PCSK9 and LIAS, and subsequently inhibits cardiomyocyte cuproptosis. In conclusion, inhibition of PCSK9 alleviates I/R-induced cardiac remodeling and dysfunction by targeting LIAS-mediated cuproptosis, which may be a novel therapeutic strategy for patients with ischemic cardiomyopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.
- Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.
- Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China. linqiuyue@firsthosp-dmu.com.
- Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China. zhangbo@dmu.edu.cn.
ORCID-Profile: Zi-Zhuo Li, Lei Guo, Yan-Liang An, Wei-Jia Yu, Ding-Yu Shi, Qiu-Yue Lin, Bo Zhang
Förderung
- Natural Science Foundation of Liaoning Province
- Department of Education of Liaoning Province
Zitieren
APA
Li, Z. Z., Guo, L., An, Y. L., Yu, W. J., Shi, D. Y., Lin, Q. Y., & Zhang, B. (2025). Evolocumab attenuates myocardial ischemia/reperfusion injury by blocking PCSK9/LIAS-mediated cuproptosis of cardiomyocytes. Basic Research in Cardiology, 120(2), 301-320. https://doi.org/10.1007/s00395-025-01100-5
Vancouver
Li ZZ, Guo L, An YL, Yu WJ, Shi DY, Lin QY, et al. Evolocumab attenuates myocardial ischemia/reperfusion injury by blocking PCSK9/LIAS-mediated cuproptosis of cardiomyocytes. Basic Research in Cardiology. 2025;120(2):301-320. doi:10.1007/s00395-025-01100-5
BibTeX
@article{Li2025,
author = {Li, Zi-Zhuo and Guo, Lei and An, Yan-Liang and Yu, Wei-Jia and Shi, Ding-Yu and Lin, Qiu-Yue and Zhang, Bo},
title = {Evolocumab attenuates myocardial ischemia/reperfusion injury by blocking PCSK9/LIAS-mediated cuproptosis of cardiomyocytes},
journal = {Basic Research in Cardiology},
year = {2025},
volume = {120},
number = {2},
pages = {301--320},
doi = {10.1007/s00395-025-01100-5}
}
EUVIMED